PERJETA targets breast cancer cells with too much HER2

In HER2+ cancer, the cancer cells have more HER2 receptors than normal cells. Targeted therapies like PERJETA and Herceptin are designed to fight these cancer cells by blocking the HER2 receptors. PERJETA and Herceptin work on different parts of the HER2 receptor, so they work together in combination with docetaxel to build a stronger blockade. Because normal cells also have some HER2 receptors, targeted therapies may affect them.

How PERJETA is designed to work

HER2 tells cancer cells to grow by sending signals


PERJETA and Herceptin target HER2

PERJETA HER2 Disruption

PERJETA for HER2+ early breast cancer before surgery

See the possible benefits and risks of PERJETA-based treatment in HER2+ early breast cancer.

PERJETA for HER2+ metastatic breast cancer

Find out about the possible benefits and risks of PERJETA for HER2+ metastatic breast cancer.